Skip to main content

Table 3 Regimens of chemotherapy

From: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

Regimen

No. of patients

%

Taxane/Cisplatin

191

47.5

Taxane/Cisplatin/5-FU

94

23.4

Irinotecan/5-FU

9

2.2

Oxaliplatin/5-FU

52

12.9

5-FU (oral or infusional fluoropyrimidines)/Cisplatin

21

5.2

Oral fluoropyrimidine

35

8.7

Total

402

100.0